Immunome Stock Up 32% in a Month: Here's What You Should Know

Impact · against what's priced in

Immunome (IMNM) is seeing a positive catalyst from the FDA's acceptance of its New Drug Application for varegacestat, providing a clear regulatory path toward a decision by April 2027. The stock's recent 31.6% rally reflects growing confidence in the drug's potential to treat desmoid tumors.

IMNM+0.60

No priced-in read yet

In context

The FDA's acceptance of the NDA for varegacestat moves the candidate closer to commercialization, with a PDUFA date set for April 28, 2027, and plans for European expansion by year-end 2026.

Read from the article alone

• biotech
• healthcare
• IMNM
• clinical trials
• desmoid tumors
• drug application
• fda
• nda
• pharma

Search tags